Clinical Trial: Metformin for the Treatment of Unexplained Oligozspermia

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia

Brief Summary: Insulin resistance (IR) in men may be the underlying pathogenesis for metabolic abnormalities and chronic hypospermatogenesis similar to women with polycystic ovarian disease (PCOD). Infertile men with unexplained infertility and IR may benefit from treatment with metformin.

Detailed Summary: Recently insulin resistance (IR) has been recognized as the underlying pathogenesis of chronic anovulation, hyperandrogenism, and metabolic abnormalities associated with PCOD in women. IR could be the underlying pathogenesis of chronic hypospermatogenesis leading to oligospermia and azoospermia associated with other metabolic abnormalities in men. Metformin has proven as an effective medication for not only IR but several other aspects of the PCOD including reproductive abnormalities. Therefore, insulin sensitizers, particularly metformin can be introduced as a pharmaceutical option for unexplained oligozoospermia and azoospermia associated with insulin resistance.
Sponsor: The Egyptian IVF-ET Center

Current Primary Outcome: sperm count [ Time Frame: 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: abnormal forms of spermatozoa [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: The Egyptian IVF-ET Center

Dates:
Date Received: February 4, 2012
Date Started: February 2012
Date Completion: February 2017
Last Updated: August 5, 2015
Last Verified: August 2015